Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: Susceptibility to receptor mutations

Molecular Pharmacology

Volumn 51, Issue 2, 1997, Pages 301-311

  Perlman, Signe ^a   Costa Neto, Claudio M ^a,c   Miyakawa, Ayumi A ^a,c   Schambye, Hans T ^a   Hjorth, Siv A ^a   Paiva, Antonio C M ^c   Rivero, Ralph A ^b   Greenlee, William J ^b   Schwartz, Thue W ^a,d  

^a Rigshospitalet   (Denmark)

^b MERCK RESEARCH LABORATORIES   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II [1 SARCOSINE 8 ISOLEUCINE]; IMIDAZOLE DERIVATIVE; L 162313; L 162389; L 162782; PARTIAL AGONIST; PHOSPHATIDYLINOSITOL; UNCLASSIFIED DRUG;

AGONIST; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL STRAIN COS1; CHEMICAL MODIFICATION; CHO CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; NONHUMAN; PHOSPHOINOSITIDE METABOLISM; POINT MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0031035850     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.51.2.301     Document Type: Article

References (39)

1. Freidinger, R. M. Towards peptide receptor ligand drugs: progress on nonpeptides. Progr. Drug Res. 40:33-98 (1993).
2. Schwartz, T. W., and S. A. Hjorth. Peptide receptors, in TiPS Receptor and Ion Channel Nomenclature Supplement 1995 (S. Watson and D. Firdlestone, eds.). 6th ed. Elsevier, Cambridge, 72 (1995).
3. 1 receptor. J. Biol. Chem. 270:1493-1496 (1995).
4. Kivlighn, S. D., W. R. Huckle, G. J. Zingaro, R. A. Rivero, V. J. Lotti, R. S. L. Chang, T. W. Schorn, N. Kevin, R. G. Johnson, Jr., W. J. Greenlee, and P. K. S. Siegl. Discovery of L-162,313: a nonpeptide that mimics the biological actions of angiotensin II. Am. J. Physiol. 268:R820-R823 (1995).
5. Aquino, C. J., D. R. Armour, J. D. Berman, L. S. Birkemo, R. A. E. Carr, D. K. Croom, M. Dezube, R. W. J. Dougherty, G. N. Ervin, M. K. Grizzle, J. E. Head, G. C. Hirst, M. K. James, M. F. Johnson, L. J. Miller, K. L. Queen, T. J. Rimele, D. N. Smith, and E. Sugg. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger." J. Med. Chem. 39:562-569 (1996).
6. Willson, T. M., B. R. Henke, T. M. Momtahen, P. L. Myers, E. E. Sugg, R. J. Unwalla, D. K. Croom, R. W. Dougherty, M. K. Grizzle, M. F. Johnson, K. L. Queen, T. J. Rimele, J. D. Yingling, and M. K. James. 3-[2-(N-Phenylacetamide))-1,5-benzodiazepines: orally active, binding selective CCK-A agonists. J. Med. Chem. 39:3030-3034 (1996).
7. Schwartz, T. W., U. Gether, H. T. Schambye, and S. A. Hjorth. Molecular mechanism of action of non-peptide ligands for peptide receptors. Curr. Pharmaceut. Design 1:325-342 (1995).
8. Schwartz, T. W. Locating ligand-binding sites in 7TM receptors by protein engineering. Curr. Opin. Biotech. 5:434-444 (1994).
9. Hjorth, S. A., H. T. Schambye, W. J. Greenlee, and T. W. Schwartz. Identification of peptide binding residues in the extracellular domains of the AT1 receptor. J. Biol. Chem. 269:30953-30959 (1994).
10. 1 receptor is essential for full agonism. J. Biol. Chem. 270:12846-12850 (1995).
11. Yamano, Y., K. Ohyama, S. Chaki, D. Guo, and T. Inagami. Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site directed mutagenesis. Biochem. Biophys. Res. Commun. 187:1426-1431 (1992).
12. 1). J. Biol. Chem. 270:14024-14030 (1995).
13. Noda, K., Y. Saad, A. Konoshita, T. P. Boyle, R. M. Graham, A. Husain, and S. S. Karnik. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J. Biol. Chem. 270:2284-2289 (1995).
14. Schambye, H. T., S. A. Hjorth, D. J. Bergsma, G. Sathe, and T. W. Schwartz. Differentiation between binding sites for angiotensin II and non-peptide antagonists on the ATI receptors. Proc. Natl. Acad. Sci. USA 91:7046-7050 (1994).
15. Ji, H., M. Leung, Y. Zhang, K. J. Catt, and K. Sandberg. Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor: identification of amino acid residues that determine binding of the antihypertensive drug, losartan. J. Biol. Chem. 269:16533-16536 (1994).
16. Schambye, H. T., S. A. Hjorth, J. Weinstock, and T. W. Schwartz. Interaction between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor. Mol. Pharmacol. 47:425-431 (1995).
17. Ji, H., W. Zheng, Y. Zhang, K. J. Catt, and K. Sandberg. Genetic transfer of a nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor. Proc. Natl. Acad. Sci. USA 92:9240-9244 (1995).
18. Rivero, R. A., N. J. Kevin, S. D. Kivlighn, G. J. Zingaro, R. S. Chang, and W. J. Greenlee. A potent orally active angiotensin II receptor antagonist with balanced affinity to both ATI and AT2 receptor subtypes. Bioorganic Med. Chem. Lett. 6:307 (1996).
19. Mantlo, N. B., P. K. Chakravarty, D. L. Odeyka, P. K. S. Siegl, R. S. L. Chang, V. J. Lotti, K. A. Faust, T. B. Chen, T. W. Schorn, C. S. Sweet, A. A. Patchett, and W. J. Greenlee. Pyridine-based angiotensin II receptor antagonists. J. Med. Chem. 34:2919-2922 (1991).
20. Bergsma, D. J., C. Ellis, P. R. Nuthulaganti, P. Nambi, K. Scaife, C. Kumar, and N. Aiyar. Isolation and expression of a novel angiotensin II receptor from Xenopus laevis heart. Mol. Pharmacol. 44:277-284 (1993).
21. Murphy, T. J., R. W. Alexander, K. K. Griendling, M. S. Runge, and K. E. Bernstein. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature (Lond.) 351:233-236 (1991).
22. Horton, R. M., H. D. Hunt, S. N. Ho, J. K. Pullen, and L. R. Pease. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61-68 (1989).
23. Johansen, T. E., M. S. Schøller, S. Tolstoy, and T. W. Schwartz. Biosynthesis of peptide precursors and protease inhibitors using new constitutive and inducible eukaryotic expression vectors. FEBS Lett. 267:289-294 (1990).
24. Gether, U., T. E. Johansen, and T. W. Schwartz. Chimeric NK1 (substance P) and NK3 (neurokinin B) receptors. J. Biol. Chem. 268:7893-7898 (1993).
25. Gether, U., X. Emonds-Alt, J.-C. Brelière, T. Fujii, D. Hagiwara, L. Pradier, C. Garret, T. E. Johansen, and T. W. Schwartz. Evidence for a common molecular mode of action for chemically distinct nonpeptide antagonists at the neurokinin-1 (substance P) receptor. Mol. Pharmacol. 45:500-508 (1994).
26. Berridge, M. J., M. C. Dawson, C. P. Downes, J. P. Heslop, and R. F. Irvin. Changes in the level of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem. J. 212:473-482 (1983).
27. Kenakin, T. Pharmacological Analysis of Drug-Receptor Interaction. 2nd ed. Raven Press, New York, 315-318 (1993).
28. Arnis, S., and K. P. Hofmann. Two different forms of metarhodopsin II: Schiff base deprotonation precedes proton uptake and signaling state. Proc. Natl. Acad. Sci. USA 90:7849-7853 (1993).
29. Arnis, S., and K. P. Hofmann. Photoregeneration of bovine rhodopsin from its signalling state. Biochemistry 34:9333-9340 (1995).
30. Scheer, A., F. Fanelli, T. Costa, P. G. De Benedetti, and S. Cotecchia. Constitutive active mutants of the α1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation. EMBO J. 15:3566-3578 (1996).
31. Ariëns, E. J. Affinity and intrinsic activity in the theory of competitive inhibition. Part 1: Problems and theory. Arch. Int. Pharmacodyn. XCIX: 32-49 (1954).
32. Szahadi, E. A model of two functionally antagonistic receptor populations activated by the same agonist. J. Theor. Biol. 69:101-112 (1977).
33. Rovati, G. E., and S. Nicosia. Lower efficacy: interaction with an inhibitory receptor or partial agonism. Trends Pharmacol. Sci. 15:140-144 (1994).
34. Fuh, G., B. C. Cunningham, R. Fukunaga, S. Nagata, D. V. Goeddel, and J. A. Wells. Rational design of potent antagonists to the human growth hormone receptor. Science (Washington D. C.) 256:1677-1680 (1992).
35. Huang, R. C., P. P. Vicario, C. D. Strader, and T. M. Fong. Identification of residues involved in ligand binding to the neurokinin-2 receptor. Biochemistry 34:10048-10055 (1994).
36. Schambye, H. T., B. van Wijk, S. A. Hjorth, W. Wienen, M. Entzeroth, D. J. Bergsma, and T. W. Schwartz. Mutations in transmembrane segment VII of the AT1 receptor differentiates between closely related insurmountable and competitive antagonists. Br. J. Pharmacol. 113:331-333 (1994).
37. 1 receptor. Trends Pharmacol. Sci. 17:123-127 (1996).
38. Schertler, G. F. X., C. Villa, and R. Henderson. Projection structure of rhodopsin. Nature (Lond.) 362:770-772 (1993).
39. Baldwin, J. M. The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 12:1693-1703 (1993).